Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06589596 · ClinicalTrials.gov registry record · Phase 1

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by BeOne Medicines.

Recruiting
Registry status
Phase 1
Development phase
244
Enrollment target
20
Study locations

NCT06589596 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeOne Medicines. The registered enrollment target is 244 participants, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06589596, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeOne Medicines.

RECRUITING
Registry status
Phase 1
Development phase
244 participants
Enrollment target
20
Study locations

Study Summary

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG BG-89894
  • DRUG BGB-58067
  • DRUG Standard of Care Therapy

Study Locations (20)

Beijing Municipality

  • Cancer Hospital Chinese Academy of Medical Sciences - Beijing
  • Beijing Cancer Hospital - Beijing
  • Beijing Chest Hospital, Capital Medical University - Beijing

Texas

  • The University of Texas Md Anderson Cancer Center - Houston
  • Next Dallas - Irving

Victoria

  • Monash Health - Clayton
  • Austin Health - Heidelberg

California

  • Usc Norris Comprehensive Cancer Center (Nccc) - Los Angeles

Florida

  • Adventhealth - Celebration

Massachusetts

  • Dana Farber Cancer Institute - Boston

Missouri

  • Washington University School of Medicine - St Louis

New York

  • Nyu Langone Health - New York

Trial Details

FieldValue
Enrollment Target 244 participants
Start Date 2024-10-11
Est. Completion 2029-01
Phase Phase 1

Sponsor

BeOne Medicines

29 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06589596

The ClinicalTrials.gov registry entry for NCT06589596 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 244 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (27% higher). The listed sponsor is BeOne Medicines, which has 29 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 3 interventions - of which BG-89894 is the first listed.

NCT06589596 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Beijing Municipality, Texas, Victoria.

Frequently Asked Questions

What is clinical trial NCT06589596 about?

NCT06589596 is a clinical study titled "An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors". This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894, and in combination with standard of care therapy ...

What is the current status of trial NCT06589596?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 244 participants. The study started on 2024-10-11. Estimated completion is 2029-01.

What conditions does trial NCT06589596 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT06589596?

The interventions under investigation include: BG-89894 (DRUG), BGB-58067 (DRUG), Standard of Care Therapy (DRUG).

Who is sponsoring clinical trial NCT06589596?

This trial is sponsored by BeOne Medicines, which has 29 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06589596 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.